

REMARKS

The Examiner has required restriction of the claimed invention, and listed the following group classifications:


Group	Claims	Description
I	1-14	methods for reducing angiogenesis or increasing apoptosis using a polynucleotide encoding a PKA catalytic subunit
II	15-18	methods for reducing angiogenesis or increasing apoptosis using a polypeptide of SEQ ID NO:114 (AVSEHQLLHS/D)
III	15-18	methods for reducing angiogenesis or increasing apoptosis using a polypeptide of SEQ ID NO:115 (SVSEIQLMNL)
IV	19-22	methods for reducing angiogenesis or increasing apoptosis using pertussis toxin
V	19-22	methods for reducing angiogenesis or increasing apoptosis using cholera toxin
VI	19-22	methods for reducing angiogenesis or increasing apoptosis using a G alpha i minigene
VII	19-22	methods for reducing angiogenesis or increasing apoptosis using a dominant negative G alpha I
VIII	19-22	methods for reducing angiogenesis or increasing apoptosis using a dominant negative G alpha 12/13
IX	19-22	methods for reducing angiogenesis or increasing apoptosis using a constitutively active G alpha s
X	19-22	methods for reducing angiogenesis or increasing apoptosis using an anti-CD47 antibody
XI	19-22	methods for reducing angiogenesis or increasing apoptosis using a dominant positive Rho (RhoV14)
XII	19-22	methods for reducing angiogenesis or increasing apoptosis using a dominant negative Src
XIII	19-22	methods for reducing angiogenesis or increasing apoptosis using a active Csk
XIV	23 & 24	methods for reducing angiogenesis or increasing apoptosis using a Src inhibitor

Applicants hereby elect to prosecute the claims of **Group I**, *without traverse* of the restriction between claim groups. Commensurate with the election, Applicants have replaced original Claims 1-24, with new Claims 25-40, in order to further the prosecution of the present application and Applicants' business interests, without acquiescing to the Examiner's arguments, and while reserving the right to prosecute the original, similar, or broader claims in one or more future application(s). Support for new Claims 25-40 directed to methods for reducing angiogenesis or increasing apoptosis can be found for instance in original Claims 1-12 of Group I, as well as in various examples. As such the amendments do not introduce new matter.

In addition, Applicants elect as single species for examination: **endothelial cell** as a cell of Claim 36; and **cancer** as a pathological condition of Claim 37. Applicants believe that the cancellation of the original claim containing a Markush group of tissue types, without introduction of a new claim containing this Markush group, obviates the requirement for election of a species of tissue for examination purposes. Thus, all of new Claims 25-40 are generic to or read upon the elected species.

Lastly, Applicants request consideration of the references listed on the Information Disclosure Statement submitted herewith, before the mailing of a first substantive Office Action. However, should the Examiner believe that a telephone interview would aid in the prosecution of this application, Applicants encourage the Examiner to call the undersigned collect.

Dated: September 5, 2007

By: 
Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500